Spero Therapeutics
SPRO
89 hedge funds and large institutions have $370M invested in Spero Therapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 13 closing their positions.
99% more capital invested
Capital invested by funds: $186M → $370M (+$184M)
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
14% more funds holding
Funds holding: 78 → 89 (+11)
5.53% more ownership
Funds ownership: 64.67% → 70.19% (+5.5%)
26% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $2.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14M |
| 2 |
BlackRock
New York
|
+$10.2M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.14M |
| 4 |
Morgan Stanley
New York
|
+$3.87M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$8.81M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.52M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$3.47M |
| 4 |
AIC
AWM Investment Company
New York
|
-$1.96M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.79M |
SPRO Hedge Fund Activity: Q4 2020 in Review
89 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2020, worth a combined $370M — up 99% from $186M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SPRO positions and 13 closed out — a net gain of 11 holders — while 34 added to existing stakes and 23 trimmed.
The largest buyer was BVF Inc, adding an estimated $14M. The largest seller was Aquilo Capital Management, cutting an estimated $8.81M.
- 89 institutional investors held Spero Therapeutics (SPRO) as of Q4 2020, up from 78 in Q3 2020.
- Funds reported $370M of Spero Therapeutics stock for Q4 2020, up 99% quarter-over-quarter.
- 24 funds opened new Spero Therapeutics positions in Q4 2020 and 13 closed out, a net change of +11 holders.
- The largest Spero Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14M added.
- The largest Spero Therapeutics seller in Q4 2020 was Aquilo Capital Management, an estimated $8.81M sold.
Based on aggregated 13F filings for Q4 2020.